Determining the value contribution of emicizumab (Hemlibra®) for the prophylaxis of haemophilia A with inhibitors in Spain by multi-criteria decision analysis
2019
Patients with moderate to severe haemophilia A are at a higher risk of developing FVIII inhibitors that require the use of more costly and less effective treatments. The objective of this study was...
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
16
References
2
Citations
NaN
KQI